Cancer Family
Lymphocytic Neoplasm
CI-CAN-00000223Explore in graph →
HematologicNon-malignant3,036 active trials72 approved drugs345 evidence items
- NCIt
- C7065
Loading cancer entity…
Cancer Family
CI-CAN-00000223Explore in graph →
Clinical trials
12,949 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07008885 | BCOR and ZC3H12 Genes Knock-out CD19-targeting CAR-T Cell Therapy in r/r B-ALL | recruiting | Phase 1 / Phase 2 | 30 | Chinese PLA General HospitalOTHER | 1 | Jun 25, 2025 | clinicaltrials |
| NCT07009002 | BCOR and ZC3H12 Genes Knock-out CD19-targeting CAR-T Cell Therapy in r/r B Cell Lymphoma | recruiting | Phase 1 / Phase 2 | 30 | Chinese PLA General HospitalOTHER | 1 | Jun 25, 2025 | clinicaltrials |
| NCT07031700 | A Multicenter, Single-Arm, Open-Label, Phase II Trial of Mosunetuzumab in Combination With Tislelizumab for r/r FL | not yet recruiting | Phase 2 | 22 | Tianjin Medical University Cancer Institute and HospitalOTHER | 0 | Jun 22, 2025 | clinicaltrials |
| NCT07032129 | Sequential CAR-T Cells Targeting BCMA/GPRC5D in Patients With Relapsed/ Refractory Multiple Myeloma(BAH2573) | recruiting | Phase 1 / Phase 2 | 60 | Essen BiotechOTHER | 1 | Jun 22, 2025 | clinicaltrials |
| NCT03817320 | PO Ixazomib in Combination With Chemotherapy for Childhood Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma | active not recruiting | Phase 1 / Phase 2 | 24 | Therapeutic Advances in Childhood Leukemia ConsortiumOTHER | 2 | Jun 17, 2025 | clinicaltrials |
| NCT06700798 | Orelabrutinib Combined With Rituximab Versus R-CVP in the Untreated MZL: A Randomized, Open Phase II Trial | recruiting | Phase 2 | 90 | Fei LiOTHER | 1 | Jun 17, 2025 | clinicaltrials |
| NCT07021677 | Use of a New Medicine "Daratumumab" to Treat Left-over Cancer in a Blood Cancer Called "T Acute Lymphoblastic Leukemia"(DARA_T_ALL) | recruiting | Phase 2 | 18 | Tata Memorial CentreOTHER | 1 | Jun 15, 2025 | clinicaltrials |
| NCT07022223 | Orelabrutinib Combined With Rituximab as First-line Systemic Treatment for Marginal Zone Lymphoma | recruiting | Phase 2 | 51 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Jun 15, 2025 | clinicaltrials |
| NCT05253495 | Chemoradiotherapy With Targeted Immunotherapy in Pediatric Lymphoma(RADICAL) | recruiting | Phase 2 | 80 | New York Medical CollegeOTHER | 1 | Jun 13, 2025 | clinicaltrials |
| NCT06862323 | Time Restricted Eating in Haematological Malignancies | not yet recruiting | Phase 2 | 75 | British Columbia Cancer AgencyOTHER | 1 | Jun 13, 2025 | clinicaltrials |
| NCT07020260 | The PACMAN-Hu19 Trial: a Study of the Safety and Feasibility of Locally Produced, CD19-targeted and Human CAR T-cell Therapy in Children and Young Adults With Relapsed or Refractory B-cell Malignancies(PACMAN) | not yet recruiting | Phase 1 / Phase 2 | 18 | Princess Maxima Center for Pediatric OncologyOTHER | 1 | Jun 13, 2025 | clinicaltrials |
| NCT07014943 | High-Dose Gemcitabine, Busulfan, and Thiotepa Followed by ASCT in Primary Central Nervous System Lymphoma | recruiting | Phase 2 | 34 | Sichuan UniversityOTHER | 1 | Jun 11, 2025 | clinicaltrials |
| NCT07012447 | Venetoclax + Azacytidine for Newly Diagnosed ETP-like ALL and T-ALL With Myeloid Mutations | recruiting | Phase 2 | 32 | yuejun LiuOTHER | 1 | Jun 10, 2025 | clinicaltrials |
| NCT07012980 | Glofitamab, Polatuzumab Vedotin and Zanubrutinib in First-line Elderly DLBCL | not yet recruiting | Phase 2 | 38 | Shanghai Zhongshan HospitalOTHER | 0 | Jun 10, 2025 | clinicaltrials |
| NCT03995147 | Pembrolizumab in Combination With Chemotherapy for Patients With Untreated B Cell Lymphoma | active not recruiting | Phase 2 | 51 | University of ChicagoOTHER | 1 | Jun 8, 2025 | clinicaltrials |
| NCT07008053 | BR Combined With OR in Treatment-naïve Marginal Zone Lymphoma | not yet recruiting | Phase 2 | 37 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jun 6, 2025 | clinicaltrials |
| NCT06414148 | MRD-Directed Consolidation With Epcor-only or Epcor-R2 Post Anti-CD19 CAR TCell Therapy for Large B-Cell Lymphoma(EpLCART) | recruiting | Phase 2 | 40 | Peter MacCallum Cancer Centre, AustraliaOTHER | 1 | Jun 5, 2025 | clinicaltrials |
| NCT06793410 | Vaccination Against Human Papillomavirus (HPV) After Allogeneic Stem Cell Transplantation | recruiting | Phase 2 | 100 | Vastra Gotaland RegionOTHER_GOV | 1 | Jun 5, 2025 | clinicaltrials |
| NCT06987916 | Efficacy and Safety Evaluation of U01(ssCART-19) in B-Cell Lymphoma | recruiting | Phase 1 / Phase 2 | 50 | Shanghai Tongji Hospital, Tongji University School of MedicineOTHER | 1 | Jun 5, 2025 | clinicaltrials |
| NCT07003464 | Phase II Trial of Zanubrutinib, Obinutuzumab, Bendamustine (ZGB) as First-Line Therapy for Chronic Lymphocytic Leukemia: A Single-Center Study | not yet recruiting | Phase 2 | 30 | The First Hospital of Jilin UniversityOTHER | 1 | Jun 4, 2025 | clinicaltrials |
| NCT06119685 | IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers | recruiting | Phase 1 / Phase 2 | 128 | Indapta Therapeutics, INC.INDUSTRY | 1 | Jun 3, 2025 | clinicaltrials |
| NCT06846489 | Acalabrutinib Plus Rituximab for the Treatment of Elderly or Low- to Intermediate-Risk Younger Untreated Mantle Cell Lymphoma | recruiting | Phase 2 | 50 | Sun Yat-sen UniversityOTHER | 1 | Jun 3, 2025 | clinicaltrials |
| NCT07000617 | A Phase II Study of Dexamethasone, Azacitidine, Pegaspargase and Tislelizumab Plus Radiotherapy for Patients With Stage I/II Extranodal NK/T-cell Lymphoma | recruiting | Phase 2 | 57 | Peking University Cancer Hospital & InstituteOTHER | 1 | Jun 3, 2025 | clinicaltrials |
| NCT07002099 | Selinexor, High-dose Methotrexate, and Rituximab Combined With Radiotherapy for Newly Diagnosed, Transplant-ineligible Patients With Central Nervous System Lymphoma: An Open-label, Single-arm, Multicenter Phase II Study | recruiting | Phase 2 | 26 | Second Affiliated Hospital of Soochow UniversityOTHER | 1 | Jun 3, 2025 | clinicaltrials |
| NCT03512405 | Pembrolizumab and Blinatumomab in Treating Participants With Recurrent or Refractory Acute Lymphoblastic Leukemia | active not recruiting | Phase 1 / Phase 2 | 36 | City of Hope Medical CenterOTHER | 1 | May 30, 2025 | clinicaltrials |
| NCT03937544 | Intravenous Autologous CD19 CAR-T Cells for R/R B-ALL | recruiting | Phase 2 / Phase 3 | 10 | National University of MalaysiaOTHER | 1 | May 29, 2025 | clinicaltrials |
| NCT06014073 | TRAC and Power3 (SPPL3) Genes Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in r/r B-NHL | recruiting | Phase 1 / Phase 2 | 30 | Chinese PLA General HospitalOTHER | 1 | May 25, 2025 | clinicaltrials |
| NCT06323525 | TCR Reserved and Power3 (SPPL3) Gene Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in r/r B Cell Lymphoma | recruiting | Phase 1 / Phase 2 | 30 | Chinese PLA General HospitalOTHER | 1 | May 25, 2025 | clinicaltrials |
| NCT06935162 | Teclistamab in Previously Treated AL Amyloidosis | recruiting | Phase 2 | 30 | Peking Union Medical College HospitalOTHER | 1 | May 25, 2025 | clinicaltrials |
| NCT01361711 | Alemtuzumab-Ofatumumab in Previously Untreated Symptomatic Chronic Lymphocytic Leukemia | active not recruiting | Phase 2 | 53 | Northwestern UniversityOTHER | 2 | May 23, 2025 | clinicaltrials |
| NCT06718244 | Inaticabtagene Autoleucel (Inati-cel; CNCT19) Treatment for MRD-Positive B-ALL Patients in CR1 | recruiting | Phase 2 | 20 | Ruijin HospitalOTHER | 1 | May 23, 2025 | clinicaltrials |
| NCT06552572 | Glofitamab in Relapsed or Refractory Diffuse Large B-cell Lymphoma After CD19 Chimeric Antigen Receptor T-cell Therapy(Glory) | active not recruiting | Phase 2 | 30 | Samsung Medical CenterOTHER | 1 | May 21, 2025 | clinicaltrials |
| NCT06034561 | Bortezomib-based Regimen for Refractory or Relapsed Acute Lymphoblastic Leukemia | recruiting | Phase 2 | 50 | Instituto do Cancer do Estado de São PauloOTHER | 1 | May 16, 2025 | clinicaltrials |
| NCT06244368 | GVM±R in Patients With Relapsed or Refractory Aggressive NHL. | recruiting | Phase 2 | 115 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | May 14, 2025 | clinicaltrials |
| NCT06971380 | Study of HBI0101 (NXC-201) CAR-T Therapy in Multiple Myeloma and Light-Chain Amyloidosis | recruiting | Phase 2 | 180 | Polina StepenskyOTHER | 1 | May 14, 2025 | clinicaltrials |
| NCT06971523 | A Phase I/II Clinical Study of CTS3497 in Patients With MTAP Deficient Malignacies | recruiting | Phase 1 / Phase 2 | 224 | CytosinLab Therapeutics Co., Ltd.INDUSTRY | 1 | May 14, 2025 | clinicaltrials |
| NCT05294055 | Mecapegfilgrastim With Chemotherapy for Peripheral Blood Stem Cell Mobilization in MM and Lymphoma | recruiting | Phase 2 | 120 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | May 13, 2025 | clinicaltrials |
| NCT05326243 | Phase 1/2 Study of CD19 Chimeric Antigen Receptor T-cell (CD19 CAR-T; PL001) for Relapsed or Refractory B-cell Lymphoma | recruiting | Phase 1 / Phase 2 | 49 | Pell Bio-Med Technology Co., Ltd.INDUSTRY | 1 | May 13, 2025 | clinicaltrials |
| NCT06925464 | CD7 CAR T-Cell Therapy for r/r T-cell Lymphomas | recruiting | Phase 1 / Phase 2 | 36 | Beijing GoBroad HospitalOTHER | 1 | May 13, 2025 | clinicaltrials |
| NCT06967038 | Chimeric Antigen Receptor Natural Killer Cell Therapy for High-risk Lymphoma Patients With Primary Sjogren's Syndrome(CAR-NK) | recruiting | Phase 1 / Phase 2 | 6 | Bangdong GongOTHER | 1 | May 13, 2025 | clinicaltrials |
| NCT06963866 | Comparing ASCT Followed by Anti-BCMA CAR-T vs. ASCT Alone in NDMM Patients Eligible for ASCT(ASCTvsCAR-T) | not yet recruiting | Phase 2 | 60 | Xuzhou Medical UniversityOTHER | 1 | May 9, 2025 | clinicaltrials |
| NCT06961500 | Obinutuzumab With CHOP Versus Obinutuzumab With Bendamustine in the Treatment of Newly Diagnosed Follicular Lymphoma Grade 3A(PROOF) | not yet recruiting | Phase 2 | 133 | Sun Yat-sen UniversityOTHER | 1 | May 8, 2025 | clinicaltrials |
| NCT06686108 | Demethylating Agents Combined With Venetoclax for High-risk T-cell Lymphoblastic Lymphoma/Leukemia Post-Transplant Relapse Prevention | recruiting | Phase 2 | 59 | Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineOTHER | 1 | May 7, 2025 | clinicaltrials |
| NCT06959732 | Zanubrutinib Combined With G-CVP in Previously Untreated FL | recruiting | Phase 2 | 40 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | May 7, 2025 | clinicaltrials |
| NCT02646839 | KIR Favorable Mismatched Haplo Transplant and KIR Polymorphism in ALL/AML/MDS Allo-HCT Children | enrolling by invitation | Phase 2 | 50 | Michael PulsipherOTHER | 1 | May 4, 2025 | clinicaltrials |
| NCT03509961 | The EndRAD Trial: Eliminating Total Body Irradiation (TBI) for NGS-MRD Negative Children, Adolescents, and Young Adults With B-ALL | recruiting | Phase 2 | 95 | Pediatric Transplantation & Cellular Therapy ConsortiumOTHER | 1 | May 4, 2025 | clinicaltrials |
| NCT04460248 | Zanubrutinib, Lenalidomide and Rituximab (ZR2) in Elderly Treatment-naive Patients With Diffuse Large B-cell Lymphoma (DLBCL) | active not recruiting | Phase 2 | 40 | Ruijin HospitalOTHER | 1 | May 2, 2025 | clinicaltrials |
| NCT05908409 | A Phase 1/2 Study of IDP-121 in Patients With Relapsed/Refractory Hematologic Malignancies(CASSANDRA) | recruiting | Phase 1 / Phase 2 | 37 | IDP Discovery Pharma S.L.INDUSTRY | 1 | May 1, 2025 | clinicaltrials |
| NCT03756896 | Carfilzomib, Pomalidomide, and Dexamethasone in Treating Patients With High-Risk Multiple Myeloma | active not recruiting | Phase 2 | 29 | Emory UniversityOTHER | 1 | Apr 30, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Jun 25, 2025source: clinicaltrials